Objective: Impaired neurocognitive function (NCF) is a well-established consequence of pediatric medulloblastoma (MB) and its treatments. However, the frequency and features of neurocognitive dysfunction in adult-onset MB patients are largely unknown.
that adult MB has a distinct biologic behavior and impact. It displays a tropism for the cerebellar hemispheres, 3 with less tendency to seed the neuraxis in comparison to pediatric MB, 4 and a distinct constellation of molecular drivers. 5 Impaired neurocognitive function (NCF) is a well-established sequela of MB in children, with late effects arising from tumor and treatment toxicity. Impairment spanning multiple cognitive domains is pervasive in patients with pediatric MB, 6 leading to functional, vocational, and social difficulties that persist into adulthood. 7 In contrast, the neurocognitive sequelae of adult-onset MB are largely unknown. Three-quarters of patients with adult MB are diagnosed between ages 21 and 40 years, 8 and this population has a demonstrated propensity for late relapse, often surviving years postdiagnosis. 9 Cognitive impairment in these patients has the potential to impact vocational responsibilities, social connections, and functional independence.
Given the unique biologic behavior of adult MB, its appropriation of the developed brain, and the differential neurotoxicity of antitumor therapies in adults, cognitive outcomes in adult patients warrant an independent investigation. The purpose of this observational, descriptive study was to characterize neurocognitive profiles in a cohort of patients with adult-onset MB and explore the clinical, disease, and treatment-related factors that may influence neurocognitive outcomes using novel approaches including lesion-symptom mapping and machine learning. Patients' demographic information, educational backgrounds, clinical and disease-related information, and treatment histories were extracted from their medical chart.
Karnofsky performance status (KPS) from the clinical visit in closest proximity to the NCE was recorded when available. If not documented, a score was extrapolated from the clinical information provided. Ascribed risk category was based on documentation in the patient's chart and, if not available, was extrapolated from radiographic and laboratory information using the Packer risk score. 10 Hydrocephalus was defined as a history of documented hydrocephalus recorded in the patient's medical chart before NCE.
Treatments received prior to NCE were documented. Extent of where there appeared to be less than 1.5 cm 2 of residual disease.
When post-operative MRI was not available (n = 12), extent of resection was determined from documentation in the medical record (ie, surgical note, imaging report, clinic notes). Craniospinal radiation therapy (RT) dose and timing with respect to NCE, and chemotherapy cycles received prior to NCE were documented.
| Neurocognitive evaluation
Neurocognitive testing was performed by a neuropsychologist, a neuropsychology fellow, or a trained psychometrist supervised by a neuropsychologist. Test scores were standardized using published demographically adjusted published z-scores (mean = 0, standard deviation = 1).
| Lesion analysis
Lesion location and size were ascertained from the MRI scan performed in closest temporal proximity to the NCE as this best represented brain structure status in association with NCF. 
| Statistical analysis
Sample characteristics were described using medians and standard deviations, or frequencies and percentages, as appropriate. Linear regression was supplemented with exploratory random forest regression (RFR). RFR was implemented using a standard approach: the square root of the number of features was split at each node, and an ensemble of 500 trees were grown by bootstrapping the features with replacement, as in our prior studies. 13 Model significance was determined based on the adjusted R-squared statistic, and Note: L = left; R = right; hemi = cerebellar hemisphere; A-P = anterior posterior; RT = radiation therapy. *Binomial test (proportion = 6%), P < 0.05. **Binomial test (proportion = 6%), P < 0.005. ***Binomial test (proportion = 16%), P < 0.005. ****Binomial test (proportion = 6%), P < 0.005.
variable importance was represented by increase in mean squared error (higher values correspond to greater variable importance).
Random forests include an intrinsic cross-validation wherein approximately one third of each bootstrap sample is left out to construct each prediction tree. 14 RFR was performed using the R Statistical Package v3.3.2 (R Foundation) including the "randomForest"
library. 15 All other statistical analyses were performed using SPSS 21.0 (IBM). 
| Sample characteristics
A total of 27 patients meeting inclusion criteria were identified (Supplementary Figure 1) . Sample characteristics are presented in Table 1 . Patients were young, well-educated, functionally fit (KPS 80 to 100) adults at the time of NCE. Most patients had already undergone some anti-tumor therapy before NCE. No patient had a documented history of cerebellar mutism. Only one patient had extra-cerebellar parenchymal findings suggestive of disseminated tumor, which were located in the occipital lobe.
| Neurocognitive test results
On average, patients with MB demonstrated impairment on multiple neurocognitive tests (Table 2) . A significant proportion of patients performed at or below the 6 th percentile (≤ −1.5 SD) on tests of verbal learning (HVLT-R TR 32%, P < 0.005), and executive function (TMTB 24%, COWA 29%, P < 0.005), as well as expressive language (Naming 18%, P < 0.05).
| Predictors of neurocognitive impairment
As shown in Table 3 and Supplementary Table 1, MLR was significant for tests of executive function including TMTB (R 2 = 0.49, P < 0.03) and similarities (R 2 = 0.61, P < 0.02). The number of chemotherapy cycles was significant for both tests, while age and education were also significant for similarities.
Random forest regression was significant for tests of attention (digit span, R 2 = 0.54, P = 0.02), processing speed (digit symbol, R 2 = 0.52, P < 0.02; TMTA, R 2 = 0.53, P < 0.02), executive function (TMTB, R 2 = 0.59, P < 0.02; Similarities, R 2 = 0.58, P < 0.03; COWA, R 2 = 0.59, P < 0.02), and visuoconstructional ability (block design, R 2 = 0.64, P < 0.02). Disease and treatment variables contributed to certain test performances, but patient education and age were the most consistent contributors, despite the neurocognitive tests being normalized for these variables (Supplementary Table 2 ).
| Lesion-symptom mapping
As shown in Figure 1 , lesions associated with worse performance on language-based tests (ie, COWA, Naming, HVLT-R TR, Similarities) generally involved the right posterior cerebellar hemisphere, whereas midline cerebellar lesions were preferentially associated with tests of memory (ie, HVLT-R DR and HVLT-R RECOG).
| CONCLUSIONS
This study identified neurocognitive impairment in adults with cerebellar MB most frequently in the domains of learning, executive function, and expressive language. To our knowledge, this is the first study of adult-onset MB that evaluated formal neurocognitive testing to identify impairment. These results expand our understanding of the clinical and biological sequelae of this tumor in adults.
The role of the cerebellum in the modulation of higher order neurocognitive processes is well recognized 23 and supports the findings of impaired NCF in patients with adult-onset MB. The Cerebellar
Cognitive Affective Syndrome denotes the neurocognitive and neurobehavioral deficits associated with cerebellar pathology 24 and is characterized by deficits in executive function, visuospatial processing, linguistic ability, and affective regulation. Clinicopathologic study and functional imaging have explored the functional topography of the cerebellum, supporting regional specialization of this structure analogous to the supratentorial brain. [25] [26] [27] The cerebellar hemispheres are proposed to subserve language functions. 25 Language was frequently impaired, perhaps explained by the prominent hemispheric involvement of adult MB. Similar to pediatric patients with MB, 6 our patients had deficits in domains of attention and processing speed. We did not find evidence of cerebellar mutism in our population. This may be due to the relative paucity of vermian involvement, as cerebellar mutism is proposed to arise from surgical perturbation of the midline dentate nuclei.
Clinician-coded lesion location was not identified as a significant Collectively, these findings suggest lesion location in adult MB likely contributes to the nature and pattern of neurocognitive dysfunction and warrants further investigation using appropriate lesion localization methodologies.
Patients' clinical features and anti-tumor treatments can impact NCF. RFR models were more often significant compared with MLR suggesting potential nonlinear relationships and/or inherent interactions between predictors and NCF, consistent with our previous studies in other cancer types. 28 Future studies should consider supplementing linear models with alternative modeling approaches when appropriate.
Age and education were the strongest patient-related predictor variables in the RFR models implying factors such as cognitive reserve, which is heavily influenced by education history, influence the impact of MB and its treatment on NCF. Chemotherapy was a significant contributor to NCF. Emerging evidence supports the use of upfront chemotherapy for both high-risk and low-risk adult MB, 29 but consideration of the increased toxicity associated with radiochemotherapy in this population remains warranted. 30 Platinum agents, lomustine, cyclophosphamide, topoisomerase inhibitors, and vinca alkaloids often are a part of the regimens employed. While the neurocognitive sequelae of all of these agents are not entirely elucidated, many have been associated with impaired NCF in prior studies. [31] [32] [33] [34] Adult patients treated with chemotherapy may also have distinct clinical or disease features;
in the current study, they were more likely to be categorized as high risk (n = 4/7). These distinct features may also contribute to poorer NCF in this patient group.
Radiation therapy dose has a significant influence on neurocognitive outcomes in pediatric MB 35 ; however, its effect in adult MB is unknown. In supratentorial gliomas, RT is associated with poorer NCF 36 and contributes to a decline in NCF over time. 37 In our analysis, its role appeared less impactful than many other variables.
However, our ability to evaluate the impact of RT may be limited by multiple factors such as the cross-sectional nature of this study (only 70% of our patients had been exposed to RT at NCE), inability to assess RT dose to specific brain volumes, and heterogeneity in time after radiation at which patients were evaluated. Unfortunately, while increased time from RT is believed to be associated with increased risk of NCF impairment, we were unable to evaluate this potential relationship.
In both MLR and RFR models, our predictor variables were not able to account for all the variance in test performance, suggesting there are other influencing variables. MB is understood to be composed of at least four distinct molecular subgroups, 5 each with its own demographic, clinical, and prognostic features. However, we did not have information regarding the molecular subgroups that constituted our sample. A recent study has revealed an association between molecular subgroup and NCF in children with MB, 38 with Sonic Hedgehog-driven tumors having the lowest incidence of cerebellar mutism and having less deterioration in processing speed compared with other subgroups, which is likely related to the preferentially hemispheric location of the tumors. Interestingly, most adult-onset MBs belong to Sonic Hedgehog subtype, 39 and yet NCE detected significant neurocognitive impairment in a substantial proportion of cases. We did not have information regarding tumor subtypes for this study, so this will be an important variable to consider in future investigations.
| Study limitations
Important limitations of this study are the small sample size, retrospective design, and cross-sectional nature, which limit our ability to delineate the relative contribution of tumor and therapy to NCF. The small sample makes MLR underpowered and RFR more prone to overfitting, so these results should be considered preliminary and hypothesis generating. Because of the broad time period over which clinical data was reviewed, there were several patients (n = 12) where post-operative MRI scans were not accessible for review. As such, the available clinical information on these patients may be more limited.
As noted above, further dissecting the impact of radiation would be of particular clinical relevance; however, our small sample size precludes further parcellation of these analyses, such as evaluating the impact of dose or radiation modality (proton versus photon) on NCF. Referral bias may have been introduced as all patients were clinically referred for formal NCE. The total number of adults with MB seen during the time period of this study at our institution was approximately 165. Therefore, only 16% were referred for NCE. While our results may illustrate a more severe phenotype than would be likely in a random sampling, patients with greater deficit would tend to have greater need for surveillance and intervention and we believe our study provides some unique insights for the clinicians that care for these patients. Isolating the impact of lesion characteristics would also benefit from prospective study. Lesion size appeared to play an important role in NCF, while lesion location carried less weight in regression analysis. Lesion mapping, however, supports a potential role for cerebellar lesion location in patient neurocognitive profiles and warrants prospective study to disentangle its contribution.
| Clinical implications
These findings provide a "snapshot" of the neurocognitive impairment 
